Nicardipine and adenosine “flush cocktail” to prevent no-reflow during rotational atherectomy

Fischell, Tim A.; Haller, Scott; Pulukurthy, Satyavardham; Virk, Imran S.

doi:10.1016/j.carrev.2008.03.002

Cited by 29 publications

(21 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…692 No-reflow after rotational atherectomy was less common with nicorandil compared with verapamil infusions in 3 studies, [693][694][695] and an infusion of nicorandil/adenosine during rotational atherectomy prevented no-reflow in 98% of patients. 677 Trials of pre-PCI intracoronary verapamil, nicardipine, and adenosine have reported them to be safe but have not demonstrated reductions in post-PCI no-reflow. 696 -698 Mechanical devices to prevent interventional and myocardial infarct reperfusion no-reflow are also covered in Section 5.5.5.…”

Section: Fondaparinux: Recommendationmentioning

confidence: 99%

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention

Levine

Bates²,

Blankenship³

et al. 2011

Circulation

1,887

567

View full text Add to dashboard Cite

Section: Fondaparinux: Recommendationmentioning

confidence: 99%

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention

Levine

Bates²,

Blankenship³

et al. 2011

Circulation

1,887

567

View full text Add to dashboard Cite

“…There are fewer data to support the use of epinephrine (692). No-reflow after rotational atherectomy was less common with nicorandil compared with verapamil infusions in 3 studies (693)(694)(695), and an infusion of nicorandil/adenosine during rotational atherectomy prevented no-reflow in 98% of patients (677). Trials of pre-PCI intracoronary verapamil, nicardipine, and adenosine have reported them to be safe but have not demonstrated reductions in post-PCI no-reflow (696 -698).…”

Section: (Level Of Evidence: B)mentioning

confidence: 95%

“…Administration of an intracoronary vasodilator (adenosine, calcium channel blocker, or nitroprusside) is reasonable to treat PCI-related no-reflow that occurs during primary or elective PCI (674)(675)(676)(677)(678)(679)(680)(681)(682)(683)(684)(685)(686)(687)(688)(689).…”

Section: Class Iiamentioning

confidence: 99%

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention

Levine¹,

Bates²,

Blankenship³

et al. 2011

Journal of the American College of Cardiology

1,980

480

View full text Add to dashboard Cite

“…1. Administration of an intracoronary vasodilator (adenosine, calcium channel blocker, or nitroprusside) is reasonable to treat PCI‐related no‐reflow that occurs during primary or elective PCI (). (Level of Evidence: B)…”

Section: Procedural Considerationsmentioning

confidence: 99%

“…There are fewer data to support the use of epinephrine (). No‐reflow after rotational atherectomy was less common with nicorandil compared with verapamil infusions in 3 studies (), and an infusion of nicorandil/adenosine during rotational atherectomy prevented no‐reflow in 98% of patients (). Trials of pre‐PCI intracoronary verapamil, nicardipine, and adenosine have reported them to be safe but have not demonstrated reductions in post‐PCI no‐reflow ().…”

Section: Procedural Considerationsmentioning

confidence: 99%